Microcap Capricor soars on interim PhII DMD data showing functional benefit for older patients
With the interim analysis for its Phase II Duchenne muscular dystrophy, little Capricor Therapeutics was merely looking for a guidepost, a signal, a trend that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.